Immunization With BCG Vaccine to Prevent Tuberculosis Infection

Tuberculosis Infection Clinical Trial

— TIPI  

Official title:

A Proof-of Concept, Randomized, Controlled Study of Tuberculosis Immunization With BCG to Prevent Infection in Healthy Adults (TIPI Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04453293
• Other study ID #: 2019-01
• Secondary ID: BAA 170090
• Status: Recruiting
• Phase: Phase 3
• Start date: December 1, 2021
• Est. completion date: May 14, 2025

Study information

• Verified date: April 2023
• Source: Henry M. Jackson Foundation for the Advancement of Military Medicine
• Contact: Kelly A. Hummer, RN, BSN
• Phone: 703-408-6273
• Email: kelly.hummer.ctr[@]usuhs.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high burden of TB. BCG will be compared with a placebo (an inactive vaccine). BCG (Japan) is used globally but is not approved for use in the United States, therefore it is considered experimental. Participants choosing to take part in this research study, will be randomly assigned (this is like a coin flip) to BCG or placebo. 2000 eligible volunteers will be enrolled.

Description:

This study is a multi-center, prospective, randomized, placebo-controlled, participant and laboratory-blinded clinical trial to evaluate a single pre-travel vaccination with investigational freeze-dried glutamate BCG (Japan) to prevent Mycobacterium tuberculosis complex (Mtb) infection in healthy adult travelers, 18-65 years of age, exposed to persons with TB in high burden countries. The goals of this study are both public health and scientific. The public health goal of this study is to offer possible protection against TB to US workers traveling abroad to work in countries with a high burden of TB where there is a risk for multidrug resistant/extensively drug resistant TB exposure and where effective TB infection control interventions are infrequently fully implemented. A long-term scientific goal is to test the hypothesis that TB vaccination prevents primary TB infection as measured by peripheral blood TB interferon gamma release assay (IGRA) conversion at return from travel visit, as well as sustained conversion at approximately 4-6 months post-return from travel. Rates of IGRA conversion in BCG-vaccinated recipients as compared to placebo recipients will be evaluated. Additionally, this study will collect information regarding exposure to and infection with TB, assessing risk factors for TB infection during the participant's travel. This study will recruit two types of travelers: Type 1 travelers (Short-term travelers) that will be limited to health care workers traveling for 4 weeks, but less than 6 months and Type 2 travelers (Long-term travelers) that will include those planning to reside in the country for 6 months or more (but ≤ 2.5 years duration), regardless of occupational group. High TB burden countries for this study are defined as countries identified in the World Health Organization (WHO) Global Tuberculosis Report 2020 to have a TB incidence of ≥70/100,000. Targeted participant population of travelers at-risk for high TB exposure will work specifically in one or more of the 74 highest ranked TB burden countries as recognized by the WHO 2020 report. Participants enrolled will be required to complete typically 4, but up to 6 study visits composed of: screening and eligibility assessments, vaccination with study vaccine (BCG or placebo), a subsequent post-vaccination follow-up assessment visit to identify potential adverse event occurrences, a post-travel follow-up visit to assess the risk factors for Mtb infection and assess the primary endpoint (IGRA conversion from negative to positive), and if applicable, an additional visit for those participants who are found to have a borderline IGRA result. For participants found to have post-travel IGRA conversion results, an additional visit will be requested for assessment of sustained TB IGRA conversion and reversion. Different evaluations, tests and/or procedures to be performed during study visits include: interviews relevant to their medical history and general well-being between study visits; physical examinations and vital signs; completion of a pre-travel questionnaire and post-travel questionnaires to collect information regarding exposure to TB and risk factors for infection, as well as any information regarding development of active TB disease, both pulmonary and/or extrapulmonary and evaluation for the presence and severity of self-reported symptomatic all-cause respiratory infection occurrences while traveling abroad; keeping a record to assess for occurrence of local reactions at the injection site and incidence of selected symptoms for the first 14 days post-vaccination; and blood draws (2 up to 4 depending on what previous blood test results reveal). The study design is endpoint driven; designed to observe 56 total IGRA conversions. Therefore, enrollment into this study will be stopped if the target endpoint (56 IGRA conversions) are met earlier than expected.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: May 14, 2025
• Est. primary completion date: May 14, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participants will be eligible for study participation if they meet all of the

following criteria:

1. Participant is willing to participate in the study as evidenced by providing voluntary written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization prior to conducting any trial related procedures

2. Participant is male or female, age = 18 years and = 65 years at time of consent

3. Participant is in good general health, confirmed by medical history, laboratory screening, and physical examination

4. Participant has no known history of Mtb infection

5. Participant has no prior history of BCG vaccination, or previous receipt of an investigational Mtb vaccine

6. Participant is assessed to be at risk for TB exposure (particularly drug resistant TB) during planned travel and has planned to work in high TB burden countries for a duration of >4 weeks and <6 months for HCW, or =6 months and =2.5 years if long term traveler and/or/HCW

7. Participant presents at least 4 weeks prior to travel departure

8. Participant is willing to forego any periodic tuberculin skin test screening procedures for 6 months after receiving BCG/placebo vaccine

9. Participant is willing to wait after receiving a COVID-19 vaccine for 7 days before receiving BCG/placebo vaccine

10. Participant is willing to complete all study visits as required by the protocol and is reachable by telephone or email during the study

11. Participant agrees to medical record access for purposes of relevant medical history collection

For Females of Childbearing Potential Only:

12. Participant has a negative urine pregnancy test prior to starting study treatment

13. Participant is willing to use effective contraception for at least 30 days before and 6 weeks after BCG/placebo vaccination

14. Lactating female that is willing to refrain from breast-feeding for 6 weeks post-vaccination

Exclusion Criteria:

• Participants will be ineligible for study participation if they meet any of the

following criteria:

1. Participant has known positive tuberculin skin test (>10 mm) or positive IGRA

2. Participant has medical condition for which BCG vaccination is contraindicated (e.g., HIV or other immunocompromised conditions)

3. Participant is currently receiving (within last 30 days) immune-compromising treatments, such as TNF-a blockade

4. Participant has history of chronic (= 30 days) oral steroid use or intravenous (IV) steroids within the last 90 days

5. Participant has received radiation therapy or chemotherapy within the last 180 days

6. Participant has received BCG treatment for bladder cancer

7. Participant is female and is pregnant (as defined by positive urine ßHCG test) or intends to become pregnant in next 3 months, or is breast-feeding at screening or vaccination visit

8. Participant is unwilling to complete all required study elements (e.g., HIV testing)

9. Participant has received 2 or more live vaccinations (e.g., measles and yellow fever) within 30 days prior to receipt of BCG/placebo vaccine (Visit 2)

10. Participant has known or suspected hypersensitivity to BCG vaccine or related products

11. Participant has positive/borderline IGRA test at screening

12. Participant has positive/indeterminate HIV test at screening

13. Participant has a history of life-threatening adverse event following receipt of any immunization

14. Participant is known to have a behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand or cooperate with the requirements of the study protocol

15. Participant has other concurrent condition(s) that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial or would render the participant unable to comply with the protocol and/or compromise study objectives

16. Participant has had tuberculin skin testing performed within 1 month prior to Visit 1

17. Participant has received a COVID-19 vaccine within 7 days prior to BCG/placebo vaccine

18. Participant has had a probable exposure to TB (defined as to someone with suspected or confirmed pulmonary TB who is likely infectious) within 8-10 weeks of Visit 1

19. Participant has prior history of nontuberculous mycobacterial disease, not colonization only

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Latent Tuberculosis
• Tuberculosis
• Tuberculosis Infection

Intervention

Biological:
• BCG (Tokyo 172) vaccine
Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region

Drug:
• Placebo
Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region

Locations

Country	Name	City	State
United States	The UAB Alabama Vaccine Research Clinic	Birmingham	Alabama
United States	The Brigham and Women's Hospital Center for Clinical Investigation	Boston	Massachusetts
United States	Hope Clinic of the Emory University Vaccine Center, Emory University	Decatur	Georgia
United States	Baylor College of Medicine	Houston	Texas
United States	Yale University	New Haven	Connecticut
United States	PENN Prevention Unit, University of Pennsylvania Division of Infectious Diseases	Philadelphia	Pennsylvania
United States	JBR Clinical Research	Salt Lake City	Utah

Sponsors (3)

Lead Sponsor	Collaborator
Henry M. Jackson Foundation for the Advancement of Military Medicine	Uniformed Services University of the Health Sciences, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in TB IGRA blood test results from baseline pre-travel and post-travel return	Conversion change of TB IGRA from pre-travel baseline value of negative to positive post-travel, using FDA-approved breakpoints as a measure of Mycobacterium tuberculosis infection. Response will be assessed using technology of the T-SPOT.TB test method. Specifically, the test measures the number of spots from T cells sensitized to TB infection on a plate containing 4 different antigens: nil (negative control), 2 TB antigens (ESAT-6 and CFP-10, also called Panel A and Panel B), and phytohemagglutinin (positive control). Results are interpreted by subtracting the spot count in the negative (NIL) control from the spot count in Panels A and B: Positive = 8 spots; Negative = 4 spots; Borderline 5, 6, or 7 spots; Invalid	At baseline, and 4-10 weeks post-travel return
Secondary	Number of Participants with sustained conversion and reversion in the TB IGRA converters	Participants identified as having positive TB IGRA blood test results will undergo a TB IGRA re-test to determine sustained (positive result) conversion and reversion (defined as negative/borderline) using the T-SPOT.TB test method. The rate of conversion for each study group will be calculated as the number of conversions divided by person-months of travel	4-6 months from return post-travel
Secondary	Number of Participants with history of TB disease/symptoms while deployed	Participants with response of symptoms suggestive of TB disease (i.e., bloody cough, cough = 2 weeks, chest pain, fever = 2 weeks, night sweats, and unintentional weight loss), development of active TB disease (possible, probable, or definite) and TB treatment that may have occurred during travel to high burden TB country or up to the time of IGRA testing	Through final IGRA testing, expected average time 4-10 weeks post-travel return
Secondary	Identify potential risk factors for Mtb infection in the targeted study population collected on Post-Travel Questionnaire	Questionnaire responses from participants after travel will collect information regarding exposure to TB and risk factors for infection, as well as any information regarding risk reduction activities taken (i.e. personal protective measures) that may have occurred during travel to countries with high burden TB identified in the 2014 World Health Organization (WHO) TB report. Travelers will be asked if they had contact with anyone known to have TB disease or if they worked with populations at risk for HIV while abroad. They will also be asked about accommodations, daily routine, and if they used public transportation such as mini-buses and if so, how frequently. A final open-ended question e.g., "Do you have reason to believe you were exposed?" will be asked of all travelers	Through final IGRA testing, expected average time 4-10 weeks post-travel return
Secondary	Number of Participants with treatment-related adverse effects following intradermal administration of BCG vaccine	Post-vaccination response to assess for occurrence of selected local injection site reactions (pain/tenderness, redness, ulceration, drainage, vesicle [blister], induration [swelling] and scarring), axillary/ cervical lymphadenopathy, and selected systemic symptoms (fever, headache, chills, dizziness, tiredness, nausea, gastrointestinal problems, rash, muscle and joint pain and general well-being) using the 2007 U.S. FDA guidance Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. For each reaction, the highest grade will be determined for each traveler. Participants will be provided with a memory aid card to record any occurrences of selected local reactions and systemic symptoms that may occur during the first 14-days post-vaccination	Baseline (pre-administration of vaccine), within 30 minutes of vaccination, 14-days post-vaccination, and 2 to 6 weeks post-vaccination (Visit 3)
Secondary	Number of Participants with self-reported symptoms of all-cause respiratory infections acquired while traveling abroad	Questionnaire responses obtained from participants will assess self-reported symptomatic all-cause respiratory infection symptoms in five domains (nose, throat, chest, systemic, neurological) for presence, frequency of occurrence and severity, impact of acute symptoms on functional activities or productivity, and medical care encounters and treatment as a result of respiratory illness while traveling abroad.	Through final IGRA testing, expected average time 4-10 weeks post-travel return